Knowable Magazine shares how studies show psychological strain can accelerate tumors and asks if beta blockers slow them down.

Topline data were announced from a phase 3 trial evaluating CTx-1301 for the treatment of pediatric patients aged 6 to 17 years with ADHD.

When we think of the symptoms of major depressive disorder (MDD) we typically think of persistent feelings of sadness, lack ...

Solriamfetol is a dopamine and norepinephrine reuptake inhibitor (DNRI), TAAR1 agonist, and 5-HT 1A agonist being developed ...

As kava gains popularity for its stress-relieving benefits, experts warn that safe use depends on tradition-informed practices, scientific evidence, and robust product regulation to prevent potential ...

Narcolepsy disrupts more than sleep—it affects daily life. Learn about causes, symptoms, diagnosis, and the latest treatment ...

In response to the FDA's feedback, Axsome plans to conduct an additional controlled trial that will use a fixed-dose paradigm ...

Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced ...

AXS-14 (esreboxetine) is a highly selective and potent norepinephrine reuptake inhibitor for the management of fibromyalgia ...

'I’m a Neuroscientist, and This 10-Second Habit Can Instantly Boost Your Focus' originally appeared on Parade.

A study found no rise in ADHD cases, though some drugs for the disorder are still in shortage amid high demand.